GPNMB and breast carcinoma: However, a study undertaken in patients with recurrent breast cancer expressing NMB glycoprotein (including both HER-2-positive tumors and TNBC), showed that this antibody had similar efficacy to conventional chemotherapy, with low objectives response rates of around 6 and 7%, respectively [81].